|
Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202. |
|
|
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical |
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International (Inst); PRA Health Sciences (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst) |
|
|
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; MSD; Ono Pharmaceutical; Taiho Pharmaceutical |
|
|
Honoraria - American Physician CME; Clarion Healthcare; Clinical Care Options; Medpage; MJH Healthcare Holdings, LLC; Oncoview; Physicans' Education Resource; Practicing Clinician Exchange; Vindico Medical Education |
Consulting or Advisory Role - Amgen; Calcium; Daichi Sankyo; Elevation Oncology; Novartis; Pinetree Therapeutics; Purple Biotech |
Research Funding - Epic Sciences; Guardant Health (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
Honoraria - AstraZeneca; AstraZeneca; Daiichi Sankyo; Deciphera; Eisai; EMD Serono; Fresenius Kabi; Genentech/Roche; Guardant Health; Ipsen; Lilly; Seagan; Stemline Therapeutics |
Consulting or Advisory Role - AstraZeneca; Deciphera; Eisai; Guardant Health; Ipsen; Lilly; Sanofi |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Deciphera; EMD Serono; Genentech/Roche; Guardant Health; Jazz Pharmaceuticals; Lilly; Pfizer; Seagan; Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fresenius Kabi; Incyte; Novartis; Regeneron; Roche/Genentech; Stemline Therapeutics; Taiho Pharmaceutical |
|
|
Honoraria - Merck; Ono Pharmaceutical; Taiho Pharmaceutical |
Consulting or Advisory Role - Chugai Pharma |
Research Funding - Lilly; Taiho Pharmaceutical |
|
|
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Miyarisan pharmaceutical; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha |
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Ono Pharmaceutical |
Research Funding - ALX Oncology (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst) |
|
|
Honoraria - Lilly Japan; Taiho Pharmaceutical; Takeda |
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Incyte; Janssen Oncology; Takeda |
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Carna Biosciences (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Amgen; Chugai Pharma; Incyte |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Aprea Therapeutics; Merus NV; Moderna Therapeutics; Zymeworks |
Research Funding - Astellas Pharma (Inst); Chungchun Intellicrown (Inst); Exelixis (Inst); IMPAC Medical Systems (Inst); Merck (Inst); Poseida (Inst); Sanofi (Inst); Synermore (Inst); Xencor (Inst) |
|
Faithlore Patrice Gardner |
Employment - Florida Cancer Specialists |
Leadership - Florida Cancer Specialists |
Speakers' Bureau - Regeneron |
Research Funding - AstraZeneca; Genentech; Lilly; Lilly; Macrogenics; Novartis Pharmaceuticals UK Ltd.; Pfizer; Pharmacyclics; Roche; Verastem |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Ono Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
Employment - Astellas Pharma |
Research Funding - Astellas Pharma |
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Karyopharm Therapeutics; Seagen |
Stock and Other Ownership Interests - Karyopharm Therapeutics; Seagen |
Travel, Accommodations, Expenses - Karyopharm Therapeutics; Seagen |
|
|
Honoraria - Chugai Pharma; Eisai; Sanofi |
Speakers' Bureau - Chugai Pharma; Eisai |
Research Funding - Abbvie (Inst); AZD (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst) |